Study of some biochemical and hematological parameters in continuously hemodialysis patients in Kirkuk city
Article Sidebar
Main Article Content
Abstract
Introduction: The severity of chronic renal failure (CRF) classified by professional guidelines in five stages, stage 5 is a severe illness often called end stage kidney failure or end stage renal disease (ESRD), dialysis may be used for this stage. Dialysis treatments replace some of these functions through diffusion (waste removal) and ultrafiltration (fluid removal). Hemodialysis, is a process of purifying the blood, when the kidneys are not working normally. It is one of three renal replacement therapies (the other two being peritoneal dialysis and renal transplant).
Materials and Methods: The samples of this study consists of 80 patients (42 males, 38 females) and 85 healthy individuals (43 males, 42 females) from (20 - 70) years old of age. Serum paraoxonase-1 (PON1), `5-nucleatidase, blood urea ( BU), serum creatinine Cr, serum iron (Fe), serum total iron binding capacity (TIBC), Serum feritin, serum amylase activity and serum lipase activity were determined. Some hematological parameters includes packed cell volume (PCV), hemoglobin (Hb), white blood cells count (WBCs), red blood cell count (RBCs) were measured, the erythrocyte sedimentation rate (ESR), Body mass index (BMI) and creatinine clearance Ccl were also measured.
Results: Decreased levels of some enzymes activity and some biochemical and hematological parameters and increased others in continuous and regular hemodialysis patients in Kirkuk city. Blood urea and serum creatinine showed significant increased (P˂0.05) in their levels, while the creatinine clearance was significantly decreased (P˂0.05) in patients with continuous hemodialysis patients when compared to those of controls. In the present study; there was significant decreased (P˂0.05) in PON-1 in patients when compared to those of controls. However, the serum`5-NT, amylase and lipase activities were significantly increased (P ˂ 0.05) in these patients when compared with serum of normal individuals. In the present study; there was significant decreased in Fe and TIBC concentrations in the serum of patients when compared to those of healthy control individuals (P˂0.05). While the serum ferritin was significantly increased (P˂0.05) in these patients as compared to the controls. In the present study; there was significant decreased (P ˂ 0.05) in Hb and PCV and RBCs concentrations inthese patients when compared to those of controls. While WBCs and ESR was significantly increased (P˂0.05) in these patients as compared to the controls.
Conclusion: Serum paraoxonase PON -1 activity is the most commonly affected than other biochemical parameters in continuous hemodialysis patients. Anemia, pancreatitis are the common and often an early complication of chronic renal diseases
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1- Levey A S, Atkins R, Coresh J, Cohen E P, Collins A J and Eckardt K U.(2007). Chronic kidney disease as a global public health problem: Approaches and initiatives -a position statement from Kidney Disease Improving Global Outcomes. Kidney International; 72: 247-259.
2- Franczyk- Skora, B., Gluba, A., Olszewski, R., Banach, M. and Rysz, J.(2014). Heart Function Disturbances in Chronic Kidney Disease – Echocardiographic Indices. Arch. Med. Sci., 10(6): 1109 - 1116.
3- Levey A S, Eckardt U and Tsukamoto Y.(2005). Definition and classification of chronic kidney disease: a position statement from Kidney Disease. Kidney International; 67: 2089–2100.
4- Cox, A. J., Hsu, F.C., Carr, J. J., Freed man, B. I., Bowden, D. W.(2013). Glomerular Filtration Rate and Albuminuria Predict Mortality Independently from Coronary Artery Calcified Plaque in the Diabetes Heart Study. Cardiovasc Diabetol., 12 : 68.
5- Degrassi, F., Quaia, E., Martingano, P., Cavallaro, M. and Cova, M.A.(2015). Imaging of Haemodialysis Renal and Extrarenal Findings. Insights Imaging, 6(3): 309 – 321.
6- Clase C., Gary A. and Kiberd B. (2004). Classifying kidney problems:
can we avoid framing risks as diseases? B.M.J., 329 (7471): 912 - 915.
7- Ahmad S, Misra M, Hoenich N, Daugirdas J.(2008). Hemodialysis Apparatus In: Handbook of Dialysis. 4th ed. New York, NY;: 59 - 78.
8- Banka CL. (1996). High Density Lipoprotein and Lipoprotein Oxidation Curr Opin Lipidol. 7: 139 - 42.
9- Aviram M, Billecke S, Sorenson R, Bisgaier C. (1998). Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves it՚s Free Sulfhydryl Group and is Different from that Required for it՚s Arylesterase / Paraoxonase Activities Arteriocler Thromb Vase Boil. 18: 1617 – 24.
10- James RW, Deakin SP. (2004). The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med. 37:1986-1994.
11- Harel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R., Dvir,H., Ravelli, R. B., McCarthy, A., Toker, L., Silman, I., Sussman, J. L., and Tawfik, D. S. (2004).Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol, 11, 412-419.
12- T. Dantoine, J. Debord, J. P. Charmes, L. Merle, and C. Leroux-Robert.(1998). “Paraoxonase activity stimulation by salts is higher in chronic renal failure patients than in controls,” Nephrology Dialysis Transplantation, vol. 13, no. 3, p. 816.
13- B. F. Henning, H. Holzhausen, and M. Tepel, (2010). “Continuous reduction of plasma paraoxonase activity with increasing dialysis vintage in hemodialysis patients,” Therapeutic Apheresis and Dialysis, vol. 14, no. 6, pp. 572–576.
14- Durrington PN, Mackness B, Mackness MI. (2001). Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 21: 473-80.
15- Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. (1991). Serum paraoxonase activity in familial hypercholesterolemia and insulin - dependent diabetes mellitus. Atherosclerosis. 86: 193-9.
16- Juretic D, Tadijanovic M, Rekic B, Simeon-Rudolf V, Reiner E, Baricic M. (2001). Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat Med J. 42: 146-50.
17- Sunderman Jr, William (1990). "The clinical biochemistry of 5'nucleotidase" (PDF). Annals of Clinical and laboratory science. 20(2). PMID 2183704. Retrieved 29 February 2016.
18- Robitaille R, Lafrance JP, Leblanc M. (2006). Altered laboratory findings associated with end-stage renal disease. Semin Dial. 19:373.
19- Taylor & Francis Group. (1971). Scandinavian Journal of Urology and Nephrology. Volume 5, Issue 3, 257-262.
20- Brugnara C, Eckardt KU. (2011). Hematologic aspects of kidney disease. In: Taal MW, ed. Brenner and Rector’s The Kidney. 9th ed. Philadelphia: Saunders. 2081–2120.
21- Damman, Kevin; Valente, Mattia A. E.; Voors, Adriaan A.; O'Connor, Christopher M.; Veldhuisen, Dirk J. van; Hillege, Hans L. (2014). "Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis". European Heart Journal 35 (7): 455 - 469.
22- Macdougall, C. (2010). Iain EK-U. Anemia in Chronic Kidney Disease. In: Jurgen
Floege RJ, John Feehally, editor Comprehensive Clinical Nephrology. Fourth ed. St. Louis, Missouri: Elsevier Saunders, 951-958.
23- Obrador, G. T, & Pereira, B. J. (2002). Anaemia of chronic kidney disease: an underrecognized and under-treated problem. Nephrol Dial Transplant, 11(17), 44-46, PMID:12386258.
24- Dhingra, R., Gaziano, J. M., & Djousse, L. (2011). Chronic kidney disease and the risk of heart failure in men. Circ Heart Fail, 4(2), 138-144, PMID: 21216838 PMCID: 3059366, 10.1161/CIRCHEARTFAILURE.109.899070.
25- Andrews, S. C.; Harrison, P. M.; Yewdall, S. J.; Arosio, P.; Levi, S.;Bottke, W.; Von Darl, M.; Briat, J.F.O. et al.(1992). "Structure, function, and evolution of ferritins". Journal of Inorganic Biochemistry 47 (3-4): 161.
26- Motchnik AP, Frei B. Ames NB.(1994). Measurement of antioxidants in human blood plasma protein thiols. In Packer L. editor . Oxigen radicals in biological systems. Califomia: Methods in Enzymology, Academic Press. pp. 234(D)pp: 273-4.
27- Wood R. J. and William D.( 1981). G.,Clin. Chem. 27(3), 464- 465.
28- Patton, C.j., Crouch, S. R., Anal Chem. (1977)49: 464 - 469.
29- Larsen, K. Clin. Chim Acta. (1972) 66, 209.
30- Ceriotti, F., and Ceriotti, G. (1980). Improved direct specific determination of serum iron. Clin. Chem. 26/2, 327. 331.
31- Ferruccio Ceriotti and Giovanni Ceriotti, (1980).Improved direct specific determination of serum iron and total iron- binding capacity. Clin. Chem. 26:327-331.
32-Vernet M. Guillemin C., Rymer JC. etal. (1994). Etude comparative de methods d’immunodosage de la ferritin serique chez des polytransfuses, L. Eurobiologist, Tom XXVІІІ, N 213/49-317.
33- Wootton I D.(1974). Microanalysis in medical biochemistry. 5th ed., Churchill living stone, Edinburgh and London, P. 236 – 237.
34- Schonebeck I, Soderberg M. (1971) Serum amylase in renal failure. Scand I Urol Nephro15; 257-262.
35- Haen, P.J. (1995).Principle of haematology . W.M.C, Brown puplishers.
36- Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL, et al. (1972). Indices of relative weight and obesity. J Chronic Dis, 25:329-343.
37- Landry DW, Bazari H. (2016). Approach to the patient with renal disease. In: Goldman L, Schafer AI, eds. Goldman - Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders. chap 114.
38-Montini, G., Pisanello, L., Dacco, V., Testa, S., Strologo, L.D., Taioli, E., Avolio, L. etal. (2003). Urea percentiles in children with chronic renal failure. Pediatric Nephrol,18:261-265.
39- Guyton, A.C., Hall, J.E. (1996). Micturition, Diuretics and Kidney Disease. In: Textbook of medical physiology. 9th ed. Philadelphia, W.B Saunders company,pp:405.
40- Khalidah S. Merzah (2015). The biochemical changes in patients with chronic renal failure International Journal of Pharma Medicine and Biological Sciences. 4, 1.
41- Ferenc Sztanek, etal. (2012). Decreased paraoxonase 1(PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease. Nephrol Dial Transplant 27: 2866 –2872.
42- Entedhar R. Sarhat1, etal. (2017). Evaluation of Serum Paraoxonase and Lipid Profile in Patients with Chronic Renal Failure Pre and post Hemodialysis. Tikrit Journal of Pure Science 22 (2). 49.
43- Melahat Dirican, etal., (2004). Bursa – Turkey. Serum paraoxonase activity in uremic predialysis and hemodialysis patients, Original Riginal Investiga Investigation J Nephrol; 17: 813-818.
44- Silva AC., Morsch AL., Zanin RF., Correa MC., Arantes LC., Araujo MC. Morsch VM. And Schetinger MR .( 2005). Biochim. Biophys. Acta, Sep 25; 1741(3): 282- 8.
45- Stefanovic V., Mitic - Zlatkovic M., Radivojevic J. and Vlahovic P. (2005). Ren. Fail.; 27 (3), 283- 8.
46- Junge, W., Mályusz, M. &Ehrens, H. J. (1985). The role of the kidney in the elimination of pancreatic lipase and amylase from blood. J. Clin. Chem. Clin. Biochem. 23, 387-392.
47- Royse, V. L., Jensen, D. M. & Corwin, H. L. (1987). Pancreatic enzymes in chronic renal failure. Arch. Intern. Med. 147, 537-539.
48- Ramesh Soundararajan, MD, FACP, Thomas A Golper, MD. (1988). Serum enzymes in patients with renal failure, Int J Artif Organs, 11:454.
49- Fahrenkurg I, Staun-Olsen P, Magid E. (1981). Irnmunore active trypsin and pancreatic isoamylase activity in serum of patients with chronic renal failure or hepatic cirrhosis. ClinChem; 27: 1655 1657.
50- Israa A .M. Jumaah. (2013). A study of some biochemical parameters in blood serum of patients with chronic renal failure. Journal of Basrah Researches ((Sciences)). 39, 4.
51- Pendse S, Singh A, Zawada E. (2008). Initiation of Dialysis. In: Handbook of Dialysis. 4th ed. New York, NY; 14–21.
52- Mojdehkar, B., Lutzky, B., Schanfrter, R., Strum, B and Goldenberg, H. (2004). Am. J. Soc. Nephrol., 15(6):1648-1655.
53- Kidney Disease. (2012). Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International Supplements. 2(4):279–335.
54- Zarychanski R, Houston DS. (2008). "Anemia of chronic disease -- aharmful disorder, or a beneficial, adaptive response?". Can. Med. Assoc. J. 179 (4): 333–7.
55- Goodnough, L.T., Skikne, B. and Brugnara, C. (2000). Erythropoietin, iron, and eryth-ropoiesis. Blood. 96:823-833.
56- Ganz, T. Hepcidin, (2003). A key regulator of iron metabolism and mediator for anemia of inflammation. Blood. 102:783-788.